JonesTrading analyst Soumit Roy has maintained their neutral stance on BOLT stock, giving a Hold rating on May 13.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Soumit Roy’s rating is based on the anticipation of upcoming data and the current stage of Bolt Biotherapeutics’ lead program. The company is expected to release preliminary Phase 1 data for their Claudin 18.2 targeting Boltbody ISAC (BDC-4182) in the first half of 2026. This data is crucial for assessing the clinical activity and competitiveness of their treatment in gastric and gastroesophageal junction cancers.
Additionally, the decision to hold is influenced by the need for more clarity on dose levels for cohort expansion and the potential selection of a partner for their dectin-2 antibody program by fall 2025. The mixed results expected from varying levels of CLDN18.2 expression in enrolled patients also contribute to the cautious stance. Until more definitive clinical data is available, the Hold rating reflects a wait-and-see approach regarding the stock’s potential.
In another report released on May 13, Stifel Nicolaus also reiterated a Hold rating on the stock with a $1.00 price target.